Aviva PLC Raises Stock Position in Veeva Systems Inc. $VEEV

Aviva PLC increased its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 5.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,447 shares of the technology company’s stock after acquiring an additional 6,297 shares during the quarter. Aviva PLC owned about 0.07% of Veeva Systems worth $33,534,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Crossmark Global Holdings Inc. purchased a new stake in Veeva Systems during the first quarter worth $299,000. Merit Financial Group LLC raised its position in shares of Veeva Systems by 12.5% in the second quarter. Merit Financial Group LLC now owns 45,247 shares of the technology company’s stock worth $13,030,000 after acquiring an additional 5,042 shares during the period. QRG Capital Management Inc. raised its position in shares of Veeva Systems by 15.7% in the second quarter. QRG Capital Management Inc. now owns 12,771 shares of the technology company’s stock worth $3,678,000 after acquiring an additional 1,735 shares during the period. Teacher Retirement System of Texas boosted its stake in shares of Veeva Systems by 1.9% during the 2nd quarter. Teacher Retirement System of Texas now owns 143,469 shares of the technology company’s stock worth $41,316,000 after acquiring an additional 2,659 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Veeva Systems by 9.3% during the 2nd quarter. Nordea Investment Management AB now owns 391,273 shares of the technology company’s stock valued at $110,832,000 after acquiring an additional 33,378 shares during the period. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Veeva Systems Stock Performance

Shares of VEEV stock opened at $295.23 on Monday. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50. The stock’s fifty day moving average is $286.40 and its two-hundred day moving average is $275.65. The firm has a market capitalization of $48.39 billion, a P/E ratio of 60.62, a PEG ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, August 27th. The technology company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). The business had revenue of $789.08 million during the quarter, compared to analyst estimates of $768.49 million. Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. Veeva Systems’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $1.62 earnings per share. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, equities analysts forecast that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Insider Transactions at Veeva Systems

In other Veeva Systems news, SVP Jonathan Faddis sold 14,595 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.00, for a total value of $4,378,500.00. Following the completion of the sale, the senior vice president directly owned 8,588 shares in the company, valued at $2,576,400. This represents a 62.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas D. Schwenger sold 3,350 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total value of $1,005,134.00. Following the completion of the sale, the insider directly owned 23,773 shares of the company’s stock, valued at $7,132,850.92. This trade represents a 12.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 24,665 shares of company stock worth $7,438,000 in the last ninety days. Insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Barclays upped their price target on Veeva Systems from $300.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, August 28th. UBS Group upped their target price on Veeva Systems from $285.00 to $310.00 and gave the stock a “neutral” rating in a research note on Thursday, August 28th. Mizuho lifted their price target on shares of Veeva Systems from $295.00 to $325.00 and gave the company an “outperform” rating in a research note on Friday, August 29th. Needham & Company LLC reissued a “buy” rating and issued a $355.00 price target on shares of Veeva Systems in a report on Friday, October 17th. Finally, Wall Street Zen cut shares of Veeva Systems from a “buy” rating to a “hold” rating in a research report on Saturday. Seventeen analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $307.58.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.